Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571

被引：3

作者：

Prejzner, W

Knopinska-Posluszny, W

Mikolajczuk, J

Langowska, B

Hellmann, A

机构：

[1] Med Acad Gdansk, Dept Haematol, PL-80211 Gdansk, Poland

[2] Med Acad Gdansk, Dept Clin Biochem, PL-80211 Gdansk, Poland

来源：

CLINICAL AND LABORATORY HAEMATOLOGY | 2003年 / 25卷 / 05期

关键词：

STI571; chronic myeloid leukemia; clonogenic capacity;

D O I：

10.1046/j.1365-2257.2003.00538.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

STI571 shows clinical activity in the treatment of chronic myelogenous leukemia, Philadelphia positive acute lymphoblastic leukemia and gastrointestinal stromal tumors. Resistance of normal progenitor cells to STI571 is essential when determining the optimal therapeutic window for patients with cancer without bone marrow involvement, and for patients with chronic myeloid leukemia who achieved complete cytogenetic remission. The effect of graded concentrations of STI571 on the clonogenic potential of normal fresh bone marrow hematopoetic progenitor cells from 13 normal individuals was analyzed. It was shown that lower concentrations of STI571 (0.1 and 0.5 mumol/l) may increase colony numbers, whereas higher concentrations (> 1 mumol/l) may reduce normal colony formation.

引用

页码：293 / 296

页数：4

共 50 条

[21] In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents
Kano, Y
Akutsu, M
Tsunoda, S
Mano, H
Sato, Y
Honma, Y
Furukawa, Y
BLOOD, 2001, 97 (07) : 1999 - 2007
[22] Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor
Frasca, F
Vigneri, P
Vella, V
Vigneri, R
Wang, JYJ
ONCOGENE, 2001, 20 (29) : 3845 - 3856
[23] STI571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy
Michael J. Mauro
Michael E. O'Dwyer
Brian J. Druker
Cancer Chemotherapy and Pharmacology, 2001, 48 : S77 - S78
[24] Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor
Francesco Frasca
Paolo Vigneri
Veronica Vella
Riccardo Vigneri
Jean Y J Wang
Oncogene, 2001, 20 : 3845 - 3856
[25] Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571
Kumar, S
Mishra, N
Raina, D
Saxena, S
Kufe, D
MOLECULAR PHARMACOLOGY, 2003, 63 (02) : 276 - 282
[26] Treatment with STI571, a tyrosine kinase inhibitor, for gastrointestinal stromal tumor with peritoneal dissemination and multiple liver metastases
Satoshi Yamamoto
Shoji Kubo
Taichi Shuto
Takatsugu Yamamoto
Kazuhiro Hirohashi
Hiromu Tanaka
Shigekazu Takemura
Akishige Kanazawa
Hiroaki Kinoshita
Journal of Gastroenterology, 2003, 38 : 896 - 899
[27] Treatment with STI571, a tyrosine kinase inhibitor, for gastrointestinal stromal tumor with peritoneal dissemination and multiple liver metastases
Yamamoto, S
Kubo, S
Shuto, T
Yamamoto, T
Hirohashi, K
Tanaka, H
Takemura, S
Kanazawa, A
Kinoshita, H
JOURNAL OF GASTROENTEROLOGY, 2003, 38 (09) : 896 - 899
[28] Comparison of the effects of the tyrosine kinase inhibitors STI571 and AG957 on bcr-abl-expressing cells, and demonstration of synergy between STI571 and the JAK2 inhibitor AG490.
Sun, XM
Elefanty, A
Layton, JE
Lieschke, GJ
BLOOD, 2000, 96 (11) : 346A - 346A
[29] Erythropoietin promotes resistance against the abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells
Kirschner, KM
Baltensperger, K
MOLECULAR CANCER RESEARCH, 2003, 1 (13) : 970 - 980
[30] Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit
Akin, C
Brockow, K
D'Ambrosio, C
Kirshenbaum, AS
Ma, YS
Longley, BJ
Metcalfe, DD
EXPERIMENTAL HEMATOLOGY, 2003, 31 (08) : 686 - 692

← 1 2 3 4 5 →